Turkish Abstract Abstract Article PDF Similar Articles Mail to Author

¹İstanbul Bilim Üniversitesi, Göz Hastalıkları A.D., İstanbul, Asist. Dr.
²İstanbul Bilim Üniversitesi, Göz Hastalıkları A.D., İstanbul, Yard. Doç. Dr.
³İstanbul Bilim Üniversitesi, Göz Hastalıkları A.D., İstanbul, Prof. Dr. Purpose: To report efficacy and our results of intravitreal bevacizumab injection for choroidal neovascularization due to age-related macula degeneration (ARMD).
Materials and Methods: One hundred four eyes of 79 patients were received 528 injections of 1.25 mg/0.05 mL intravitreal bevacizumab and followed at least one year. Every patient has received injections once a month for 3 consecutive months. Intravitreal reinjections of bevacizumab were administered according to visual acuity (VA) measurements, fundus fluorescein angiography (FFA) and optic coherens tomography (OCT) results.
Results: According to mean VA results, 48 eyes (46.2%) had an increase of 5 letters and more. Fifty eyes (48.1%) had no change and 6 eyes (5.7%) had a decrease of 5 letters and more in 3th month. After 12 month follow-up VA results were 43 eyes (41.3%) had an increase of 5 letters and more, 53 eyes (50.9%) had no change and 8 eyes (7.7%) had a decrease of 5 letters and more,. Central macular thickness (CMT) were; in 75 eyes (72.1%) decreased by 100 μm and more, in 23 eyes (22.1%) had no change and in 6 eyes (5.8%) increased by 100 μm and more in 3th month. After 12 month follow-up CMT results were 70 eyes (67.3%) decreased by 100 μm and more, 27 eyes (26.0%) had no change and 7 eyes (6.7%) increased by 100 μm and more.
Conclusions: Intravitreal bevacizumab provides significant anatomic and functional improvement compared baseline in choroidal neovascularization due to ARMD. Keywords : Intravitreal bevacizumab, age related macula degeneration, neovascularization